Search results

I've written a blog post that summarizes some of the findings on cell type and tissue enrichment posted in this thread: https://mecfsscience.org/cell-and-tissue-enrichment-in-me-cfs/

Thanks. I suspect they are a bit too confident about this. The only way to be sure that there's a subgroup that responds is to do a new randomized trial in this subgroup only and compare the treatment versus a placebo. What they seem to be doing is, after a trial finished and produced null...

Yes, I think @wallfish explained it well. These are the BPS people from Belgium and they see ME/CFS like a sort of stress-related burnout. There are some biological measurements in this study that might be interesting like the PET scans but am afraid that most will be interpreted in light of...

I don't fully understand, though, because it is quite likely that inebilizumab will turn out to be ineffective. So then this follow-up study with tafasitimab would no longer be indicated?

Yes

Someone has looked into it on Twitter:

Not sure, but I suspect it would be bigger because the standardized effect size was a Cohen's d of 0.56. That is usually larger than the minimal clinically important difference. Think the biggest problems of this trial lie elsewhere: no control condition, no objective outcomes, no correction...

Anyone able to find the trial registration? Don't see it either and they mention 5 primary outcomes. With correction none would be statistically significant. Post-hoc usually means that it wasn't pre-specified and decided after seeing the results. Don't think the ANCOVA versus MMRM...

Positive news again, hope many people will apply.

In addition, the treatment effects were not clinically significant from what I can see. They defined the minimally clinically important difference (MCID) for the primary outcome (the FAS) as a change of 3 points. The FAS benefits compared to no treatment were : -1.49 points [95% CI –2·92 to...

Looks like a clear result. I think people will say it's in tissues like the gut, not in the blood, but I wonder if that theory holds.

Ah sorry, could be that I misunderstood this.

I suspect the daratumumab trial would be the quickest way to get a breakthrough, but it's very uncertain whether it will bring positive results. The underlying scientific evidence, in my (amateur) opinion, is not very strong. The genetic data from DecodeME looks more robust, but it probably has...

One caveat here is that if you look at the raw numbers in supplementary table 2, the rate with infectious onset was almost identical. An infectious onset was reported by 61.1% in the high symptom burden group compared to 61.2% in the low symptom burden group. So this doesn't separate them at...

I think we also have to take into account that progress will likely not be linear. There are self-reinforcing trends, such as new researchers who bring in other researchers or provide helpful peer review in the grant decision process. Especially when there will be a (small) breakthrough and a...

Isn't this what the results would look like if you don't find meaningful clusters or subgroups? Almost 50% split with only modest differences between the two groups. The paper writes: "This large-scale cluster analysis of DecodeME symptom data reinforces that ME/CFS is a heterogeneous...

Thanks for sharing. One notable trend is how much is happening in Europe compared to the US. Things used to be the exact opposite only a couple of year ago. It looked almost impossible to get Horizon Europe funding for ME/CFS. The number of respected research group across the continent could be...

There must also be an error in the effect size reported in table 3. With such low sample size a cohen d of 0.107 would never be statistically significant. They probably also misspelled the standard deviation for the patient group in the table (it should likely be 0.086 instead of 0.86).

The meta-GWAS (DME_1 + MVP)

Wrote more about this here: The symptom signaling theory of ME/CFS involving neurons and their synapses | Science for ME Don't see the issue with triggering versus maintaining the disease being two separate problems. Suppose the issue is overfiring of a neural network involved in fatigue and...